A phase 3, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) in combination with axitinib (INLYTA(registered)) versus sunitinib (SUTENT(registered)) monotherapy in the first-line treatment of patients with advanced renal cell carcinoma. NCT02684006
A phase 3, randomized, open-label study of nivolumab combined with cabozantinib versus sunitinib in participants with previously untreated advanced or metastatic renal cell carcinoma. NCT03141177
A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma. NCT02231749
A phase III randomized, open-label study to evaluate efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (KEYNOTE-426).NCT02853331
Choueiri TK et al. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. ESMO 2020;Abstract 696O_PR.
Lee CH et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). ASCO 2020;Abstract 5008.
Motzer RJ et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103-15. Abstract
Motzer RJ et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019;20(10):1370-85. Abstract
Motzer RJ et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277-90. Abstract
Powles T et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): Phase III KEYNOTE-426 study. ASCO Genitourinary Cancers Symposium 2019;Abstract 543.
Rini BI et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116-27. Abstract